AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Results of Operations and Financial Condition

AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

Story continues below

On November8, 2017, Avadel Pharmaceuticals plc (the “Company”) issued a press release announcing its earnings for the third quarter ended September30, 2017. That press release is attached as Exhibit 99.1 and is incorporated herein by reference.

The information responsive to this Item 2.02 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

On November 8, 2017, the Company posted to its website a set of presentation materials in conjunction with its earnings call and webcast to assist participants with understanding the Company’s financial results for the quarter ended September 30, 2017. A copy of this presentation is attached hereto as Exhibit 99.2.

The information responsive to this Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

* This information shall be deemed to be "furnished" and not filed herewith.


AVADEL PHARMACEUTICALS PLC Exhibit
EX-99.1 2 q32017earningsrelease.htm EXHIBIT 99.1 Exhibit Avadel Pharmaceuticals Reports Third Quarter 2017 ResultsTotal Revenues for the Third Quarter Were $39.7 millionFull Year Revenue Guidance of $165-$175 million UnchangedAcquired License for Noctiva™ Dublin,…
To view the full exhibit click here

An ad to help with our costs